Everolimus-d4;EveroliMus-d4 (~90%);EVEROLIMUS (2-HYDROXYETHYL-D4, 98%);Everolimus-d4 (Everolimus Impurity);Everolimus Impurity 24(Everolimus-d4);Everolimus D4Q: What is
Everolimus D4 Q: What is the CAS Number of
Everolimus D4 Q: What is the storage condition of
Everolimus D4 Q: What are the applications of
Everolimus D4
장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴
특정 표적장기 독성 - 반복 노출
구분 1
위험
P260, P264, P270, P314, P501
예방조치문구:
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P264
취급 후에는 손을 철저히 씻으시오.
P264
취급 후에는 손을 철저히 씻으시오.
P270
이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P314
불편함을 느끼면 의학적인 조치·조언을 구하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
EveroliMus-d4 C화학적 특성, 용도, 생산
개요
Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM. It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin. Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer. It also acts as an immunosuppressive agent in the context of organ transplantation.
일반 설명
A stable-labeled internal standard for the immunosuppressant Everolimus, marketed as Zortress? and Certican for use in organ transplantation and Afinitor? for treatment of kidney and pancreatic cancers. Clinical laboratories quantitate everolimus levels in patient whole blood samples using LC-MS/MS. While many everolimus LC-MS/MS methods use 32-desmethoxyrapamycin or ascomycin as an internal standard, higher levels of variability / lower levels of reproducibility may occur in the analysis along with the potential for interferences. Use of a stable-labeled analog of everolimus is the best choice to minimize variability or mitigate any potential interference in LC-MS/MS analysis.
